LIFECORE BIOMEDICAL, INC. Proceeds from Lines of Credit
LIFECORE BIOMEDICAL, INC. (LFCR) reported Proceeds from Lines of Credit of $1.91 million for the 3-month period ending 2024-08-25, per its 10-Q filed 2024-10-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2024-10-04
- LIFECORE BIOMEDICAL, INC. proceeds from lines of credit for the quarter ending 2024-08-25 was $1.91M, a 16.09% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. proceeds from lines of credit for the quarter ending 2023-11-26 was -$2.21M, a 155.30% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. proceeds from lines of credit for the quarter ending 2023-08-27 was $2.28M, a 42.97% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. proceeds from lines of credit for the quarter ending 2023-05-28 was $13.05M, a 29.21% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. proceeds from lines of credit for fiscal 2024 was $149.59M, a 375.63% increase from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. proceeds from lines of credit for fiscal 2023 was $31.45M, a 42.93% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. proceeds from lines of credit for fiscal 2022 was $55.11M, a 44.89% decline from fiscal 2021.
- LIFECORE BIOMEDICAL, INC. proceeds from lines of credit for fiscal 2021 was $100.00M, a 16.18% decline from fiscal 2020.
| Period end | Proceeds from Lines of Credit | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 6 month as first filed | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|---|---|
| 2024-08-25 | $1.91M 10-Q · filed 2024-10-04 | |||||
| 2024-05-26 | $149.59M 10-K · filed 2024-08-26 | |||||
| 2023-11-26 | -$2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $69.00K 10-Q · filed 2024-08-09 | $13.12M derived: sum of 3 quarters · filed 2024-10-04 | $23.52M derived: sum of 4 quarters · filed 2024-10-04 | ||
| 2023-08-27 | $2.28M 10-Q · filed 2024-10-04 | $15.33M derived: sum of 2 quarters · filed 2024-10-04 | $25.73M derived: sum of 3 quarters · filed 2024-10-04 | $29.73M derived: sum of 4 quarters · filed 2024-10-04 | ||
| 2023-05-28 | $13.05M derived: 10-K 12 month − 10-K 9 month · filed 2024-08-26 | $23.45M derived: sum of 2 quarters · filed 2024-08-26 | $27.45M derived: sum of 3 quarters · filed 2024-08-26 | $31.45M 10-K · filed 2024-08-26 | ||
| 2023-02-26 | $10.40M derived: 10-K 9 month − 10-Q 6 month · filed 2024-03-20 | $14.40M derived: sum of 2 quarters · filed 2024-08-09 | $18.40M 10-K · filed 2024-03-20 | $28.50M derived: sum of 4 quarters · filed 2024-08-26 | ||
| 2022-11-27 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $8.00M 10-Q · filed 2024-08-09 | $8.80M 10-Q · filed 2023-03-16 | $18.10M derived: sum of 3 quarters · filed 2024-08-26 | $37.11M derived: sum of 4 quarters · filed 2024-08-26 | |
| 2022-08-28 | $4.00M 10-Q · filed 2024-08-09 | $14.10M derived: sum of 2 quarters · filed 2024-08-26 | $33.11M derived: sum of 3 quarters · filed 2024-08-26 | $51.11M derived: sum of 4 quarters · filed 2024-08-26 | ||
| 2022-05-29 | $10.10M derived: 10-K 12 month − 10-K 9 month · filed 2024-08-26 | $29.11M derived: sum of 2 quarters · filed 2024-08-26 | $47.11M derived: sum of 3 quarters · filed 2024-08-26 | $55.11M 10-K · filed 2024-08-26 | ||
| 2022-02-27 | $19.01M derived: 10-K 9 month − 10-K 6 month · filed 2024-03-20 | $37.01M derived: sum of 2 quarters · filed 2024-03-20 | $45.01M 10-K · filed 2024-03-20 | $62.01M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2021-11-28 | $18.00M derived: 10-K 6 month − 10-K 3 month · filed 2024-03-20 | $26.00M 10-K · filed 2024-03-20 | $43.00M derived: sum of 3 quarters · filed 2024-03-20 | $102.00M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2021-08-29 | $8.00M 10-K · filed 2024-03-20 | $25.00M derived: sum of 2 quarters · filed 2024-03-20 | $84.00M derived: sum of 3 quarters · filed 2024-03-20 | $97.00M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2021-05-30 | $17.00M derived: 10-K 12 month − 10-K 9 month · filed 2024-03-20 | $76.00M derived: sum of 2 quarters · filed 2024-03-20 | $89.00M derived: sum of 3 quarters · filed 2024-03-20 | $100.00M 10-K · filed 2024-03-20 | ||
| 2021-02-28 | $59.00M derived: 10-K 9 month − 10-Q 6 month · filed 2024-03-20 | $72.00M derived: sum of 2 quarters · filed 2024-03-20 | $83.00M 10-K · filed 2024-03-20 | $117.90M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2020-11-29 | $13.00M derived: 10-Q 6 month − 10-K 3 month · filed 2022-01-07 | $24.00M 10-Q · filed 2022-01-07 | $58.90M derived: sum of 3 quarters · filed 2024-03-20 | $80.40M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2020-08-30 | $11.00M 10-K · filed 2024-03-20 | $45.90M derived: sum of 2 quarters · filed 2024-03-20 | $67.40M derived: sum of 3 quarters · filed 2024-03-20 | $95.30M derived: sum of 4 quarters · filed 2024-03-20 | ||
| 2020-05-31 | $34.90M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-16 | $56.40M derived: sum of 2 quarters · filed 2023-03-16 | $84.30M derived: sum of 3 quarters · filed 2023-03-16 | $119.30M 10-K/A · filed 2023-03-16 | ||
| 2020-02-23 | $21.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-04-08 | $49.40M derived: sum of 2 quarters · filed 2021-04-08 | $84.40M 10-Q · filed 2021-04-08 | $109.40M derived: sum of 4 quarters · filed 2021-07-29 | ||
| 2019-11-24 | $27.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-01-07 | $62.90M 10-Q · filed 2021-01-07 | $87.90M derived: sum of 3 quarters · filed 2021-07-29 | $106.90M derived: sum of 4 quarters · filed 2021-07-29 | ||
| 2019-08-25 | $35.00M 10-Q · filed 2020-10-07 | $60.00M derived: sum of 2 quarters · filed 2021-07-29 | $79.00M derived: sum of 3 quarters · filed 2021-07-29 | $82.00M derived: sum of 4 quarters · filed 2021-07-29 | ||
| 2019-05-26 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-29 | $44.00M derived: sum of 2 quarters · filed 2021-07-29 | $47.00M derived: sum of 3 quarters · filed 2021-07-29 | $59.00M 10-K · filed 2021-07-29 | ||
| 2019-02-24 | $19.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-04-03 | $22.00M derived: sum of 2 quarters · filed 2020-04-03 | $34.00M 10-Q · filed 2020-04-03 | $49.00M derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2018-11-25 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-01-02 | $15.00M 10-Q · filed 2020-01-02 | $30.00M derived: sum of 3 quarters · filed 2020-08-14 | $33.50M derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2018-08-26 | $12.00M 10-Q · filed 2019-10-03 | $27.00M derived: sum of 2 quarters · filed 2020-08-14 | $30.50M derived: sum of 3 quarters · filed 2020-08-14 | $34.50M derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2018-05-27 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-14 | $18.50M derived: sum of 2 quarters · filed 2020-08-14 | $22.50M derived: sum of 3 quarters · filed 2020-08-14 | $33.00M 10-K · filed 2020-08-14 | ||
| 2018-02-25 | $3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-04-04 | $7.50M derived: sum of 2 quarters · filed 2019-04-04 | $18.00M 10-Q · filed 2019-04-04 | $21.00M derived: sum of 4 quarters · filed 2019-08-01 | ||
| 2017-11-26 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-01-07 | $14.50M 10-Q · filed 2019-01-07 | $17.50M derived: sum of 3 quarters · filed 2019-08-01 | $17.50M derived: sum of 4 quarters · filed 2019-08-01 | ||
| 2017-08-27 | $10.50M 10-Q · filed 2018-10-05 | $13.50M derived: sum of 2 quarters · filed 2019-08-01 | $13.50M derived: sum of 3 quarters · filed 2019-08-01 | |||
| 2017-05-28 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-08-01 | $3.00M derived: sum of 2 quarters · filed 2019-08-01 | $4.50M 10-K · filed 2019-08-01 | |||
| 2017-02-26 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-04-05 | $1.50M 10-Q · filed 2018-04-05 | ||||
| 2016-11-27 | $1.50M 10-Q · filed 2018-01-05 | |||||
| 2016-09-24 | $1.50M 10-Q · filed 2017-01-05 | |||||
| 2016-05-29 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-09 | $15.60M derived: sum of 2 quarters · filed 2018-08-09 | $26.10M 10-K · filed 2018-08-09 | |||
| 2016-02-28 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-04-07 | $19.50M 10-Q · filed 2017-04-07 | ||||
| 2015-11-29 | $10.50M 10-Q · filed 2017-01-05 | |||||
| 2015-05-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | $5.30M derived: sum of 2 quarters · filed 2018-03-15 | $19.30M derived: sum of 3 quarters · filed 2018-03-15 | $30.42M 10-K/A · filed 2018-03-15 | ||
| 2015-03-01 | $5.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-30 | $19.30M derived: sum of 2 quarters · filed 2016-03-30 | $30.42M 10-Q · filed 2016-03-30 | $36.42M derived: sum of 4 quarters · filed 2016-08-01 | ||
| 2014-11-30 | $14.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-01-07 | $25.12M 10-Q · filed 2016-01-07 | $31.12M derived: sum of 3 quarters · filed 2016-08-01 | |||
| 2014-08-31 | $11.12M 10-Q · filed 2015-10-01 | $17.12M derived: sum of 2 quarters · filed 2016-08-01 | ||||
| 2014-05-25 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-01 | $9.50M 10-K · filed 2016-08-01 | ||||
| 2014-02-23 | $3.50M 10-Q · filed 2015-04-02 | |||||
| 2012-05-27 | $12.77M 10-K · filed 2014-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |